Skip to main content
Top
Published in: Trials 1/2017

Open Access 01-12-2017 | Review

A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?

Authors: Ana Rath, Valérie Salamon, Sandra Peixoto, Virginie Hivert, Martine Laville, Berenice Segrestin, Edmund A. M. Neugebauer, Michaela Eikermann, Vittorio Bertele, Silvio Garattini, Jørn Wetterslev, Rita Banzi, Janus C. Jakobsen, Snezana Djurisic, Christine Kubiak, Jacques Demotes-Mainard, Christian Gluud

Published in: Trials | Issue 1/2017

Login to get access

Abstract

Background

Evidence-based clinical practice is challenging in all fields, but poses special barriers in the field of rare diseases. The present paper summarises the main barriers faced by clinical research in rare diseases, and highlights opportunities for improvement.

Methods

Systematic literature searches without meta-analyses and internal European Clinical Research Infrastructure Network (ECRIN) communications during face-to-face meetings and telephone conferences from 2013 to 2017 within the context of the ECRIN Integrating Activity (ECRIN-IA) project.

Results

Barriers specific to rare diseases comprise the difficulty to recruit participants because of rarity, scattering of patients, limited knowledge on natural history of diseases, difficulties to achieve accurate diagnosis and identify patients in health information systems, and difficulties choosing clinically relevant outcomes.

Conclusions

Evidence-based clinical practice for rare diseases should start by collecting clinical data in databases and registries; defining measurable patient-centred outcomes; and selecting appropriate study designs adapted to small study populations. Rare diseases constitute one of the most paradigmatic fields in which multi-stakeholder engagement, especially from patients, is needed for success. Clinical research infrastructures and expertise networks offer opportunities for establishing evidence-based clinical practice within rare diseases.
Appendix
Available only for authorised users
Footnotes
1
Funded by the European Union Framework Programme 7 (EU FP7; grant agreement no. 284395), ECRIN-IA involved 23 countries and brought together diverse stakeholders to overcome barriers to clinical research in three particularly difficult areas (rare diseases, medical devices, and nutrition). Specifically, the project aimed to develop tools, services, and infrastructure to facilitate multinational clinical research in Europe, and to support the development of pan-European disease networks to drive clinical projects. This in turn was intended to improve Europe’s attractiveness to industry, boost its scientific competitiveness, and result in better healthcare for European citizens. Originally planned for 4 years (2012 to 2015), the clinical trials work package was extended until 2017.
 
Literature
1.
go back to reference Garattini S, Jakobsen JC, Wetterslev J, Bertele V, Banzi R, Rath A, et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. Eur J Intern Med. 2016;32:13–21. Epub 11 May 2016.CrossRefPubMed Garattini S, Jakobsen JC, Wetterslev J, Bertele V, Banzi R, Rath A, et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. Eur J Intern Med. 2016;32:13–21. Epub 11 May 2016.CrossRefPubMed
3.
go back to reference Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intractable Rare Dis Res. 2012;1(1):3–9. Epub 1 Feb 2012.PubMedPubMedCentral Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intractable Rare Dis Res. 2012;1(1):3–9. Epub 1 Feb 2012.PubMedPubMedCentral
7.
go back to reference Schlander M, Garattini S, Holm S, Kolominsky-Rabas P, Nord E, Persson U, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Effectiveness Res. 2014;3(4):399–422. Epub 3 Oct 2014.CrossRef Schlander M, Garattini S, Holm S, Kolominsky-Rabas P, Nord E, Persson U, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Effectiveness Res. 2014;3(4):399–422. Epub 3 Oct 2014.CrossRef
8.
go back to reference Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014;9:170. Epub 28 Nov 2014.CrossRefPubMedPubMedCentral Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014;9:170. Epub 28 Nov 2014.CrossRefPubMedPubMedCentral
17.
go back to reference Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013;69(4):1009–24. Epub 24 Oct 2012.CrossRefPubMed Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013;69(4):1009–24. Epub 24 Oct 2012.CrossRefPubMed
18.
go back to reference Westermark K, Holm BB, Soderholm M, Llinares-Garcia J, Riviere F, Aarum S, et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov. 2011;10(5):341–9. Epub 3 May 2011. Westermark K, Holm BB, Soderholm M, Llinares-Garcia J, Riviere F, Aarum S, et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov. 2011;10(5):341–9. Epub 3 May 2011.
21.
go back to reference Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. ‘Adaptive pathways’ to drug authorisation: adapting to industry? BMJ. 2016;354:i4437. Epub 18 Aug 2016.CrossRefPubMed Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. ‘Adaptive pathways’ to drug authorisation: adapting to industry? BMJ. 2016;354:i4437. Epub 18 Aug 2016.CrossRefPubMed
23.
go back to reference Eichler HG, Oye K, Baird LG, Abadie E, Brown J, Drum CL, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012;91(3):426–37. Epub 18 Feb 2012.CrossRefPubMed Eichler HG, Oye K, Baird LG, Abadie E, Brown J, Drum CL, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012;91(3):426–37. Epub 18 Feb 2012.CrossRefPubMed
24.
go back to reference Demotes-Mainard J, Kubiak C. A European perspective—the European clinical research infrastructures network. Ann Oncol. 2011;22 Suppl 7:vii44–9. Epub 9 Nov 2011.CrossRefPubMed Demotes-Mainard J, Kubiak C. A European perspective—the European clinical research infrastructures network. Ann Oncol. 2011;22 Suppl 7:vii44–9. Epub 9 Nov 2011.CrossRefPubMed
25.
go back to reference Djurisic S, Rath A, Gaber S, Garattini S, Bertele V, Ngwabyt SN, et al. Barriers to the conduct of randomised clinical trials within all disease areas. Trials. 2017;18(1):360.CrossRefPubMedPubMedCentral Djurisic S, Rath A, Gaber S, Garattini S, Bertele V, Ngwabyt SN, et al. Barriers to the conduct of randomised clinical trials within all disease areas. Trials. 2017;18(1):360.CrossRefPubMedPubMedCentral
26.
go back to reference Laville M, Segrestin B, Masson Y, Ruano-Rodríguez C, Serra-Majem L, Hyesmaye M, et al. Evidence-based practice within nutrition: what are the barriers for improving the evidence and how can they be dealt with? Trials. 2017;18(1):425. Laville M, Segrestin B, Masson Y, Ruano-Rodríguez C, Serra-Majem L, Hyesmaye M, et al. Evidence-based practice within nutrition: what are the barriers for improving the evidence and how can they be dealt with? Trials. 2017;18(1):425.
27.
go back to reference Neugebauer EAM, Rath A, Antoine S-L, Eikermann M, Seidel D, Koenen C, et al. Specific barriers to the conduct of randomised clinical trials on medical devices. Trials. 2017;18(1):427. Neugebauer EAM, Rath A, Antoine S-L, Eikermann M, Seidel D, Koenen C, et al. Specific barriers to the conduct of randomised clinical trials on medical devices. Trials. 2017;18(1):427.
28.
go back to reference Valdez R, Ouyang L, Bolen J. Public health and rare diseases: oxymoron no more. Prev Chronic Dis. 2016;13:E05. Epub 15 Jan 2016.PubMedPubMedCentral Valdez R, Ouyang L, Bolen J. Public health and rare diseases: oxymoron no more. Prev Chronic Dis. 2016;13:E05. Epub 15 Jan 2016.PubMedPubMedCentral
29.
go back to reference Shash E, Negrouk A, Marreaud S, Golfinopoulos V, Lacombe D, Meunier F. International clinical trials setting for rare cancers: organisational and regulatory constraints-the EORTC perspective. Ecancermedicalscience. 2013;7:321. Epub 30 May 2013.CrossRefPubMedPubMedCentral Shash E, Negrouk A, Marreaud S, Golfinopoulos V, Lacombe D, Meunier F. International clinical trials setting for rare cancers: organisational and regulatory constraints-the EORTC perspective. Ecancermedicalscience. 2013;7:321. Epub 30 May 2013.CrossRefPubMedPubMedCentral
30.
go back to reference Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14(10):681–91. Epub 4 Sep 2013.CrossRefPubMed Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14(10):681–91. Epub 4 Sep 2013.CrossRefPubMed
33.
go back to reference Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28(9):1142–50. Epub 10 Sep 2013.CrossRefPubMedPubMedCentral Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28(9):1142–50. Epub 10 Sep 2013.CrossRefPubMedPubMedCentral
34.
go back to reference Rath A, Olry A, Dhombres F, Brandt MM, Urbero B, Ayme S. Representation of rare diseases in health information systems: the Orphanet approach to serve a wide range of end users. Hum Mutat. 2012;33(5):803–8. Epub 17 Mar 2012.CrossRefPubMed Rath A, Olry A, Dhombres F, Brandt MM, Urbero B, Ayme S. Representation of rare diseases in health information systems: the Orphanet approach to serve a wide range of end users. Hum Mutat. 2012;33(5):803–8. Epub 17 Mar 2012.CrossRefPubMed
38.
go back to reference Rodger S, Lochmuller H, Tassoni A, Gramsch K, Konig K, Bushby K, et al. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J Rare Dis. 2013;8:171. Epub 24 Oct 2013. Rodger S, Lochmuller H, Tassoni A, Gramsch K, Konig K, Bushby K, et al. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J Rare Dis. 2013;8:171. Epub 24 Oct 2013.
39.
go back to reference Potter BK, Khangura SD, Tingley K, Chakraborty P, Little J. Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? Genet Med. 2016;18(2):117–23. Epub 10 Apr 2015.CrossRefPubMed Potter BK, Khangura SD, Tingley K, Chakraborty P, Little J. Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? Genet Med. 2016;18(2):117–23. Epub 10 Apr 2015.CrossRefPubMed
40.
go back to reference Tudur Smith C, Williamson PR, Beresford MW. Methodology of clinical trials for rare diseases. Best Pract Res Clin Rheumatol. 2014;28(2):247–62. Epub 30 Jun 2014.CrossRefPubMed Tudur Smith C, Williamson PR, Beresford MW. Methodology of clinical trials for rare diseases. Best Pract Res Clin Rheumatol. 2014;28(2):247–62. Epub 30 Jun 2014.CrossRefPubMed
41.
go back to reference Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol. 2011;64(10):1085–94. Epub 3 May 2011.CrossRefPubMed Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol. 2011;64(10):1085–94. Epub 3 May 2011.CrossRefPubMed
42.
go back to reference Korn EL, McShane LM, Freidlin B. Statistical challenges in the evaluation of treatments for small patient populations. Sci Transl Med. 2013;5(178):178sr3. Epub 29 Mar 2013.CrossRefPubMed Korn EL, McShane LM, Freidlin B. Statistical challenges in the evaluation of treatments for small patient populations. Sci Transl Med. 2013;5(178):178sr3. Epub 29 Mar 2013.CrossRefPubMed
43.
go back to reference Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis. 2013;8:48. Epub 28 Mar 2013.CrossRefPubMedPubMedCentral Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, et al. Experimental designs for small randomised clinical trials: an algorithm for choice. Orphanet J Rare Dis. 2013;8:48. Epub 28 Mar 2013.CrossRefPubMedPubMedCentral
44.
go back to reference Gagne JJ, Thompson L, O’Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802. Epub 26 Nov 2014.CrossRefPubMedPubMedCentral Gagne JJ, Thompson L, O’Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802. Epub 26 Nov 2014.CrossRefPubMedPubMedCentral
45.
go back to reference Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14(5):365–76. Epub 11 Apr 2013.CrossRefPubMed Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14(5):365–76. Epub 11 Apr 2013.CrossRefPubMed
46.
47.
go back to reference Hilgers RD, Roes K, Stallard N. Directions for new developments on statistical design and analysis of small population group trials. Orphanet J Rare Dis. 2016;11(1):78. Epub 16 Jun 2016.CrossRefPubMedPubMedCentral Hilgers RD, Roes K, Stallard N. Directions for new developments on statistical design and analysis of small population group trials. Orphanet J Rare Dis. 2016;11(1):78. Epub 16 Jun 2016.CrossRefPubMedPubMedCentral
48.
go back to reference Roes KC. A framework: make it useful to guide and improve practice of clinical trial design in smaller populations. BMC Med. 2016;14(1):195. Epub 26 Nov 2016.CrossRefPubMedPubMedCentral Roes KC. A framework: make it useful to guide and improve practice of clinical trial design in smaller populations. BMC Med. 2016;14(1):195. Epub 26 Nov 2016.CrossRefPubMedPubMedCentral
49.
go back to reference Nikolakopoulos S, Roes KC, van der Tweel I. Sequential designs with small samples: evaluation and recommendations for normal responses. Stat Methods Med Res. 2016. Epub 28 Jun 2016. Nikolakopoulos S, Roes KC, van der Tweel I. Sequential designs with small samples: evaluation and recommendations for normal responses. Stat Methods Med Res. 2016. Epub 28 Jun 2016.
50.
go back to reference Ioannidis JP, Hozo I, Djulbegovic B. Optimal type I and type II error pairs when the available sample size is fixed. J Clin Epidemiol. 2013;66(8):903–10. e2 Epub 15 May 2013.CrossRefPubMed Ioannidis JP, Hozo I, Djulbegovic B. Optimal type I and type II error pairs when the available sample size is fixed. J Clin Epidemiol. 2013;66(8):903–10. e2 Epub 15 May 2013.CrossRefPubMed
51.
go back to reference Vickers AJ, Scardino PT. The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost. Trials. 2009;10:14. Epub 7 Mar 2009.CrossRefPubMedPubMedCentral Vickers AJ, Scardino PT. The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost. Trials. 2009;10:14. Epub 7 Mar 2009.CrossRefPubMedPubMedCentral
53.
go back to reference Mauer M, Collette L, Bogaerts J. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size. Eur J Cancer. 2012;48(9):1386–91. Epub 28 Jan 2012.CrossRefPubMed Mauer M, Collette L, Bogaerts J. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size. Eur J Cancer. 2012;48(9):1386–91. Epub 28 Jan 2012.CrossRefPubMed
54.
go back to reference Tamura RN, Krischer JP, Pagnoux C, Micheletti R, Grayson PC, Chen YF, et al. A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemp Clin Trials. 2016;46:48–51. Epub 21 Nov 2015.CrossRefPubMed Tamura RN, Krischer JP, Pagnoux C, Micheletti R, Grayson PC, Chen YF, et al. A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemp Clin Trials. 2016;46:48–51. Epub 21 Nov 2015.CrossRefPubMed
57.
go back to reference Billingham L, Malottki K, Steven N. Research methods to change clinical practice for patients with rare cancers. Lancet Oncol. 2016;17(2):e70–80. Epub 13 Feb 2016.CrossRefPubMed Billingham L, Malottki K, Steven N. Research methods to change clinical practice for patients with rare cancers. Lancet Oncol. 2016;17(2):e70–80. Epub 13 Feb 2016.CrossRefPubMed
66.
go back to reference Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol. 2007;46(4):734–42. Epub 24 Feb 2007.CrossRefPubMed Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol. 2007;46(4):734–42. Epub 24 Feb 2007.CrossRefPubMed
67.
go back to reference Molenberghs G, Geys H, Buyse M. Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes. Stat Med. 2001;20(20):3023–38. Epub 9 Oct 2001.CrossRefPubMed Molenberghs G, Geys H, Buyse M. Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes. Stat Med. 2001;20(20):3023–38. Epub 9 Oct 2001.CrossRefPubMed
68.
go back to reference Molenberghs G, Burzykowski T, Alonso A, Assam P, Tilahun A, Buyse M. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. Stat Methods Med Res. 2010;19(3):205–36. Epub 18 Jul 2009.CrossRefPubMed Molenberghs G, Burzykowski T, Alonso A, Assam P, Tilahun A, Buyse M. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. Stat Methods Med Res. 2010;19(3):205–36. Epub 18 Jul 2009.CrossRefPubMed
69.
go back to reference Ensor H, Lee RJ, Sudlow C, Weir CJ. Statistical approaches for evaluating surrogate outcomes in clinical trials: a systematic review. J Biopharm Stat. 2015:1–21. Epub 24 Sep 2015. Ensor H, Lee RJ, Sudlow C, Weir CJ. Statistical approaches for evaluating surrogate outcomes in clinical trials: a systematic review. J Biopharm Stat. 2015:1–21. Epub 24 Sep 2015.
70.
go back to reference Joppi R, Gerardi C, Bertele V, Garattini S. Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ. 2016;353:i2978. Epub 24 Jun 2016.CrossRefPubMed Joppi R, Gerardi C, Bertele V, Garattini S. Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ. 2016;353:i2978. Epub 24 Jun 2016.CrossRefPubMed
72.
go back to reference Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J. The thresholds for statistical and clinical significance—a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med Res Methodol. 2014;14:34. Epub 5 Mar 2014.CrossRefPubMedPubMedCentral Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J. The thresholds for statistical and clinical significance—a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med Res Methodol. 2014;14:34. Epub 5 Mar 2014.CrossRefPubMedPubMedCentral
73.
go back to reference Perea-Milla E, Aycaguer LC, Cerda JC, Saiz FG, Rivas-Ruiz F, Danet A, et al. Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index. Trials. 2009;10:70. Epub 18 Aug 2009.CrossRefPubMedPubMedCentral Perea-Milla E, Aycaguer LC, Cerda JC, Saiz FG, Rivas-Ruiz F, Danet A, et al. Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index. Trials. 2009;10:70. Epub 18 Aug 2009.CrossRefPubMedPubMedCentral
74.
go back to reference Putzeist M, Mantel-Teeuwisse AK, Wied CC, Hoes AW, Leufkens HG, de Vrueh RL. Drug development for exceptionally rare metabolic diseases: challenging but not impossible. Orphanet J Rare Dis. 2013;8:179. Epub 19 Nov 2013.CrossRefPubMedPubMedCentral Putzeist M, Mantel-Teeuwisse AK, Wied CC, Hoes AW, Leufkens HG, de Vrueh RL. Drug development for exceptionally rare metabolic diseases: challenging but not impossible. Orphanet J Rare Dis. 2013;8:179. Epub 19 Nov 2013.CrossRefPubMedPubMedCentral
78.
go back to reference Matza LS, Patrick DL, Riley AW, Alexander JJ, Rajmil L, Pleil AM, et al. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health. 2013;16(4):461–79. Epub 26 Jun 2013.CrossRefPubMed Matza LS, Patrick DL, Riley AW, Alexander JJ, Rajmil L, Pleil AM, et al. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health. 2013;16(4):461–79. Epub 26 Jun 2013.CrossRefPubMed
80.
go back to reference Tafuri G, Pagnini M, Moseley J, Massari M, Petavy F, Behring A, et al. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. Br J Clin Pharmacol. 2016;82(4):965–73. Epub 2 Jun 2016. Tafuri G, Pagnini M, Moseley J, Massari M, Petavy F, Behring A, et al. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. Br J Clin Pharmacol. 2016;82(4):965–73. Epub 2 Jun 2016.
81.
82.
go back to reference Forman J, Taruscio D, Llera VA, Barrera LA, Cote TR, Edfjall C, et al. The need for worldwide policy and action plans for rare diseases. Acta Paediatr. 2012;101(8):805–7. Epub 24 Apr 2012.CrossRefPubMedPubMedCentral Forman J, Taruscio D, Llera VA, Barrera LA, Cote TR, Edfjall C, et al. The need for worldwide policy and action plans for rare diseases. Acta Paediatr. 2012;101(8):805–7. Epub 24 Apr 2012.CrossRefPubMedPubMedCentral
84.
go back to reference Bajard A, Chabaud S, Cornu C, Castellan AC, Malik S, Kurbatova P, et al. An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials. J Clin Epidemiol. 2016;69:125–36. Epub 19 Jul 2015.CrossRefPubMed Bajard A, Chabaud S, Cornu C, Castellan AC, Malik S, Kurbatova P, et al. An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials. J Clin Epidemiol. 2016;69:125–36. Epub 19 Jul 2015.CrossRefPubMed
85.
go back to reference Bolignano D, Pisano A. Good-quality research in rare diseases: trials and tribulations. Pediatr Nephrol. 2016;31:217-23. Epub 29 Jan 2016. Bolignano D, Pisano A. Good-quality research in rare diseases: trials and tribulations. Pediatr Nephrol. 2016;31:217-23. Epub 29 Jan 2016.
87.
go back to reference Ahmed R, Duerr U, Gavenis K, Hilgers R, Gross O. Challenges for academic investigator-initiated pediatric trials for rare diseases. Clin Ther. 2014;36(2):184–90. Epub 18 Feb 2014.CrossRefPubMed Ahmed R, Duerr U, Gavenis K, Hilgers R, Gross O. Challenges for academic investigator-initiated pediatric trials for rare diseases. Clin Ther. 2014;36(2):184–90. Epub 18 Feb 2014.CrossRefPubMed
88.
go back to reference Friede T, Rover C, Wandel S, Neuenschwander B. Meta-analysis of few small studies in orphan diseases. Res Synth Methods. 2016;8:79-91. Epub 30 Jun 2016. Friede T, Rover C, Wandel S, Neuenschwander B. Meta-analysis of few small studies in orphan diseases. Res Synth Methods. 2016;8:79-91. Epub 30 Jun 2016.
89.
go back to reference Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64–75. Epub 18 Dec 2007.CrossRefPubMed Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64–75. Epub 18 Dec 2007.CrossRefPubMed
90.
go back to reference Imberger G, Thorlund K, Gluud C, Wetterslev J. False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review. BMJ Open. 2016;6(8):e011890. Epub 16 Aug 2016.CrossRefPubMedPubMedCentral Imberger G, Thorlund K, Gluud C, Wetterslev J. False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review. BMJ Open. 2016;6(8):e011890. Epub 16 Aug 2016.CrossRefPubMedPubMedCentral
91.
go back to reference Kulinskaya E, Wood J. Trial sequential methods for meta-analysis. Res Synth Methods. 2014;5(3):212–20. Epub 9 Jun 2015.CrossRefPubMed Kulinskaya E, Wood J. Trial sequential methods for meta-analysis. Res Synth Methods. 2014;5(3):212–20. Epub 9 Jun 2015.CrossRefPubMed
93.
go back to reference Alberts B, Kirschner MW, Tilghman S, Varmus H. Rescuing US biomedical research from its systemic flaws. Proc Natl Acad Sci U S A. 2014;111(16):5773–7. Epub 16 Apr 2014.CrossRefPubMedPubMedCentral Alberts B, Kirschner MW, Tilghman S, Varmus H. Rescuing US biomedical research from its systemic flaws. Proc Natl Acad Sci U S A. 2014;111(16):5773–7. Epub 16 Apr 2014.CrossRefPubMedPubMedCentral
94.
go back to reference Ioannidis JP, Fanelli D, Dunne DD, Goodman SN. Meta-research: evaluation and improvement of research methods and practices. PLoS Biol. 2015;13(10):e1002264. Epub 3 Oct 2015.CrossRefPubMedPubMedCentral Ioannidis JP, Fanelli D, Dunne DD, Goodman SN. Meta-research: evaluation and improvement of research methods and practices. PLoS Biol. 2015;13(10):e1002264. Epub 3 Oct 2015.CrossRefPubMedPubMedCentral
95.
go back to reference Gotzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials. 1996;17(4):285–90. discussion 90–3 Epub 1 Aug 1996.CrossRefPubMed Gotzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials. 1996;17(4):285–90. discussion 90–3 Epub 1 Aug 1996.CrossRefPubMed
96.
go back to reference MacCoun R, Perlmutter S. Blind analysis: hide results to seek the truth. Nature. 2015;526(7572):187–9. Epub 10 Oct 2015.CrossRefPubMed MacCoun R, Perlmutter S. Blind analysis: hide results to seek the truth. Nature. 2015;526(7572):187–9. Epub 10 Oct 2015.CrossRefPubMed
98.
go back to reference Jarvinen TL, Sihvonen R, Bhandari M, Sprague S, Malmivaara A, Paavola M, et al. Blinded interpretation of study results can feasibly and effectively diminish interpretation bias. J Clin Epidemiol. 2014;67(7):769–72. Epub 25 Feb 2014.CrossRefPubMed Jarvinen TL, Sihvonen R, Bhandari M, Sprague S, Malmivaara A, Paavola M, et al. Blinded interpretation of study results can feasibly and effectively diminish interpretation bias. J Clin Epidemiol. 2014;67(7):769–72. Epub 25 Feb 2014.CrossRefPubMed
Metadata
Title
A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?
Authors
Ana Rath
Valérie Salamon
Sandra Peixoto
Virginie Hivert
Martine Laville
Berenice Segrestin
Edmund A. M. Neugebauer
Michaela Eikermann
Vittorio Bertele
Silvio Garattini
Jørn Wetterslev
Rita Banzi
Janus C. Jakobsen
Snezana Djurisic
Christine Kubiak
Jacques Demotes-Mainard
Christian Gluud
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Trials / Issue 1/2017
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-017-2287-7

Other articles of this Issue 1/2017

Trials 1/2017 Go to the issue